Composition and method for treatment and prophylaxis of intestinal infection and inflammation

Abstract

The present invention relates to a composition for use in the treatment and/or prevention of a gastrointestinal condition, comprising at least one Lactobacillus strain, wherein the Lactobacillus strain is chosen from the group consisting of one L. salivarius strain, three L. plantarum strains and one L. brevis strain, wherein the L. salivarius strain is L. salivarius CW30 (LMG P-28887), wherein the L. plantarum strains are L. plantarum Y1An734 (LMG P-28886), L. plantarum SH1313 (LMG P-28884), and L. plantarum KS1 1 (LMG P-28885), and wherein the L. brevis strain is L. brevis SH1 1 1 (LMG P-28888). The present invention also relates to an enema comprising a composition according to the present invention. The present invention also relates to an isolated strain chosen from the group L. salivarius CW30 (LMG P-28887), L. plantarum Y1An734 (LMG P-28886), L. plantarum SH1313 (LMG P-28884), L. plantarum KS11 (LMG P-28885) and L. brevis SH111 (LMG P-28888). The present invention also relates to an isolated strain of L. salivarius CW30 (LMG P-28887) for use in the treatment and/or prevention of an infection by Clostridium difficile NAP/027.

Description

TECHNICAL FIELD OF THE INVENTION[0001]The present invention relates to a composition for use in the treatment and / or prevention of a gastrointestinal condition, comprising at least one Lactobacillus strain. Especially, the Lactobacillus strain may be a L. salivarius strain, a L. plantarum strain and / or a L. brevis strain and the gastrointestinal condition may be a bacterial infection by Clostridium difficile, Salmonella or Escherichia coli. BACKGROUND[0002]The mammalian intestine is colonized by an estimated 100 trillion bacteria, which have co-evolved with the host in a symbiotic relationship. This collection of microbial populations in the host is referred to as the microbiota. The microbiota can efficiently protect the intestine against colonization by exogenous pathogens and potentially harmful indigenous microorganisms (pathobionts). Mucosal immune responses to normal intestinal bacteria are also important for development and physiology of the host. Breakdown in immunological t...

AI Technical Summary

Benefits of technology

[0025]The gastrointestinal condition may be irritable bowel syndrome (IBS) or inflammatory bowel disease (IBD). The term inflammatory bowel disease (IBD) includes, among other conditions, Crohn's disease and ulcerative colitis.

[0026]The gastrointestinal condition may also be pouchitis or post infection colitis.

[0027]The composition may be administered orally, such as in a beverage or food product. The composition may be administered as a beverage, in which case the Lactobacillus strain(s) are suspended in a liquid. The liquid may e.g. be water, milk, a salt-sugar solution or a gruel. Alternatively, the composition may be administered as a porridge or pudding. The composition may be included in a pill, which can be swallowed by the patient. An advantage of these routes of administration is that they do not require any advanced medical equipment. Another advantage of administering the composition as a beverage, porridge, pudding or pill is that the patient can control when the beverage, porridge, pudding or pill is swallowed.

[0028]The composition may be administered as an enema. An advantage of this route of administration is that it can be per

Problems solved by technology

Breakdown in immunological tolerance to microbiota lead to inappropriate local and systemic immune responses to intestinal bacterial communities that may contribute to multiple disease states such as inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS).

Alteration in the balance of the intestinal microbiota results in disrupted intestinal homeostasis, which increases the risk of pathogen infection and the overgrowth of pathobionts, particularly in immunocompromised hosts.

However, recurrence (occurs in 10 to 25% of cases) is getting increasingly common and represent the greatest challenge associated with CD infections (CDI).

The major changes in the epidemiology of CDI during recent years, with increases in incidence and severity of disease have made it a global public health challenge.

Although their high clinical cure rates, 15-30% of patients still experience a recurrence, with each recurrence increasing the risk of further infections.

Such transplantation, in addition to the possible psychological discomfort, may also pose the risk of transplanting potentially harmful microorganisms from the donor.

Thus, although fecal microbiota transplant has demonstrated some promising results for treating CDI, physicians are concerned about potential infection

Images